Cullinan Management Advances SLE Treatment with CLN-978 Trial
Company Announcements

Cullinan Management Advances SLE Treatment with CLN-978 Trial

An announcement from Cullinan Management ( (CGEM) ) is now available.

Cullinan Therapeutics has announced the initiation of a global Phase 1 clinical trial in Australia for its innovative CD19xCD3 bispecific T cell engager, CLN-978, aimed at treating systemic lupus erythematosus (SLE). This step marks a significant advancement in the company’s commitment to addressing autoimmune diseases with potential best-in-class treatments. CLN-978 is designed to be a convenient and potent off-the-shelf therapy, targeting B cells with high precision, potentially revolutionizing the standard of care for SLE patients who currently rely on lifelong immune suppression.

See more data about CGEM stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCullinan Therapeutics reports Q3 EPS (69c), consensus (81c)
TheFlyCullinan Therapeutics sees cash runway into 2028
TheFlyCullinan Therapeutics to present preclinical data for CLN-978
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App